Skip to main content

Table 4 Microbiologic results by bedaquiline treatment in MDR-TB patients in South Africa

From: Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis

 

Bedaquiline

N = 3739a

No bedaquiline

N = 2231a

Sputum culture at baseline

  

 Positive, n (%)

2483 (85.5)

1358 (80.3)

 Negative, n (%)

420 (14.5)

334 (19.7)

 Missing, n

836

539

Sputum culture conversionb

  

 To negative, n/N (%)

2084/2483 (83.9)

868/1358 (63.9)

 Non-conversion, n/N (%)

399/2483 (16.1)

490/1358 (36.1)

Sputum culture reversionc

  

 To positive, n/N (%)

127/2084 (6.1)

25/868 (2.9)

Times to sputum culture initial conversion

N = 2483

N = 1358

Median, days

102

83

95% CI

98, 106

78, 88

  1. CI confidence interval, The 95% CI is based on the Clopper-Pearson exact binomial method
  2. aThe 11 patients excluded from the evaluable population were 4 patients that were still on treatment (all bedaquiline-treated) and 7 patients with missing treatment outcome (4 bedaquiline-treated patients and 3 non-bedaquiline-treated patients)
  3. bPercentage is based on the number who were positive at baseline and their status at two consecutive visits at least 30 days apart: negative (conversion) or positive (non-conversion); Baseline was defined as the most recent result/measurement prior to the first dose
  4. cPercentage is based on the number who had a conversion to negative